183 related articles for article (PubMed ID: 10492237)
21. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
Canto EI; Singh H; Shariat SF; Lamb DJ; Mikolajczyk SD; Linton HJ; Rittenhouse HG; Kadmon D; Miles BJ; Slawin KM
Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
[TBL] [Abstract][Full Text] [Related]
22. Histopathologic characterization of hereditary benign prostatic hyperplasia.
Doehring CB; Sanda MG; Partin AW; Sauvageot J; Juo H; Beaty TH; Epstein JI; Hill G; Walsh PC
Urology; 1996 Oct; 48(4):650-3. PubMed ID: 8886078
[TBL] [Abstract][Full Text] [Related]
23. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
24. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
25. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
Tsukamoto T; Masumori N; Rahman M; Crane MM
Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
[TBL] [Abstract][Full Text] [Related]
26. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
[TBL] [Abstract][Full Text] [Related]
27. Watchful waiting in benign prostatic hyperplasia.
Wiygul J; Babayan RK
Curr Opin Urol; 2009 Jan; 19(1):3-6. PubMed ID: 19057209
[TBL] [Abstract][Full Text] [Related]
28. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
29. Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a vascular disease?
Berger AP; Horninger W; Bektic J; Pelzer A; Spranger R; Bartsch G; Frauscher F
BJU Int; 2006 Sep; 98(3):587-90. PubMed ID: 16796699
[TBL] [Abstract][Full Text] [Related]
30. Ursolic acid reduces prostate size and dihydrotestosterone level in a rat model of benign prostatic hyperplasia.
Shin IS; Lee MY; Jung DY; Seo CS; Ha HK; Shin HK
Food Chem Toxicol; 2012 Mar; 50(3-4):884-8. PubMed ID: 22266360
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
32. Reduced circulating androgen bioactivity in patients with prostate cancer.
Raivio T; Santti H; Schatzl G; Gsur A; Haidinger G; Palvimo JJ; Jänne OA; Madersbacher S
Prostate; 2003 May; 55(3):194-8. PubMed ID: 12692785
[TBL] [Abstract][Full Text] [Related]
33. Could inflammation be a key component in the progression of benign prostatic hyperplasia?
Kramer G; Marberger M
Curr Opin Urol; 2006 Jan; 16(1):25-9. PubMed ID: 16385197
[TBL] [Abstract][Full Text] [Related]
34. The origin and development of benign prostatic hyperplasia. An age-dependent process.
Oesterling JE
J Androl; 1991; 12(6):348-55. PubMed ID: 1722790
[TBL] [Abstract][Full Text] [Related]
35. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
Te AE; Malloy TR; Stein BS; Ulchaker JC; Nseyo UO; Hai MA
BJU Int; 2006 Jun; 97(6):1229-33. PubMed ID: 16686717
[TBL] [Abstract][Full Text] [Related]
36. Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
Abdel-Khalek M; Sheir KZ; El-Baz M; Ibrahiem el-H
Scand J Urol Nephrol; 2005; 39(1):49-55. PubMed ID: 15764271
[TBL] [Abstract][Full Text] [Related]
37. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
38. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.
Stamey TA; Warrington JA; Caldwell MC; Chen Z; Fan Z; Mahadevappa M; McNeal JE; Nolley R; Zhang Z
J Urol; 2001 Dec; 166(6):2171-7. PubMed ID: 11696729
[TBL] [Abstract][Full Text] [Related]
39. The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men.
Shannon BA; Cohen RJ; Garrett KL
BJU Int; 2008 Feb; 101(4):429-35. PubMed ID: 17850358
[TBL] [Abstract][Full Text] [Related]
40. Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats.
Golomb E; Rosenzweig N; Eilam R; Abramovici A
J Androl; 2000; 21(1):58-64. PubMed ID: 10670520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
